X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs DIVIS LABORATORIES - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA DIVIS LABORATORIES TORRENT PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 27.2 30.0 90.8% View Chart
P/BV x 5.2 5.2 99.6% View Chart
Dividend Yield % 1.1 1.0 110.4%  

Financials

 TORRENT PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
DIVIS LABORATORIES
Mar-17
TORRENT PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,7681,222 144.7%   
Low Rs1,186784 151.2%   
Sales per share (Unadj.) Rs346.1153.1 226.1%  
Earnings per share (Unadj.) Rs55.239.9 138.1%  
Cash flow per share (Unadj.) Rs73.344.6 164.4%  
Dividends per share (Unadj.) Rs14.0010.00 140.0%  
Dividend yield (eoy) %0.91.0 95.1%  
Book value per share (Unadj.) Rs257.1201.8 127.4%  
Shares outstanding (eoy) m169.22265.47 63.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.36.6 65.1%   
Avg P/E ratio x26.825.1 106.6%  
P/CF ratio (eoy) x20.122.5 89.6%  
Price / Book Value ratio x5.75.0 115.6%  
Dividend payout %25.425.0 101.4%   
Avg Mkt Cap Rs m249,887266,266 93.8%   
No. of employees `00011.89.7 121.0%   
Total wages/salary Rs m9,9344,687 211.9%   
Avg. sales/employee Rs Th4,971.54,175.0 119.1%   
Avg. wages/employee Rs Th843.2481.5 175.1%   
Avg. net profit/employee Rs Th792.41,089.3 72.7%   
INCOME DATA
Net Sales Rs m58,56940,643 144.1%  
Other income Rs m2,233749 298.2%   
Total revenues Rs m60,80241,392 146.9%   
Gross profit Rs m13,77314,460 95.2%  
Depreciation Rs m3,0691,233 248.9%   
Interest Rs m2,05623 9,095.6%   
Profit before tax Rs m10,88113,953 78.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5453,349 46.1%   
Profit after tax Rs m9,33610,604 88.0%  
Gross profit margin %23.535.6 66.1%  
Effective tax rate %14.224.0 59.2%   
Net profit margin %15.926.1 61.1%  
BALANCE SHEET DATA
Current assets Rs m53,84140,105 134.2%   
Current liabilities Rs m31,6126,595 479.4%   
Net working cap to sales %38.082.5 46.0%  
Current ratio x1.76.1 28.0%  
Inventory Days Days97119 82.0%  
Debtors Days Days8481 103.8%  
Net fixed assets Rs m42,07919,995 210.4%   
Share capital Rs m846531 159.4%   
"Free" reserves Rs m42,65553,043 80.4%   
Net worth Rs m43,50153,574 81.2%   
Long term debt Rs m22,4080-   
Total assets Rs m101,25061,585 164.4%  
Interest coverage x6.3618.4 1.0%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.7 87.7%   
Return on assets %11.317.3 65.2%  
Return on equity %21.519.8 108.4%  
Return on capital %19.626.1 75.2%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m20,06635,384 56.7%   
Fx outflow Rs m5,30410,399 51.0%   
Net fx Rs m14,76224,985 59.1%   
CASH FLOW
From Operations Rs m10,12711,493 88.1%  
From Investments Rs m-7,869-11,372 69.2%  
From Financial Activity Rs m-1,918-93 2,060.2%  
Net Cashflow Rs m21228 744.7%  

Share Holding

Indian Promoters % 71.5 52.0 137.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 11.8 59.5%  
FIIs % 12.6 19.0 66.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.2 51.2%  
Shareholders   26,511 31,796 83.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   CIPLA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS